EMA Warns of Respreeza Vial Integrity Issues

The European Medicines Agency (EMA) has issued a Direct Healthcare Professional Communication (DHPC) regarding Respreeza, a human alpha1-proteinase inhibitor. The alert highlights a risk of compromised vial integrity, which could lead to missed doses and potential infections for patients. This communication provides crucial information for healthcare professionals involved in prescribing, dispensing, or administering the medication to ensure patient safety.